Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M110,252Revenue $M43,451Net Margin (%)19.3Z-Score2.5
Enterprise Value $M136,090EPS $3.6Operating Margin %25.3F-Score7
P/E(ttm))14.5Cash Flow Per Share $0Pre-tax Margin (%)23.7Higher ROA y-yY
Price/Book11.110-y EBITDA Growth Rate %3.0Quick Ratio0.8Cash flow > EarningsY
Price/Sales2.85-y EBITDA Growth Rate %2.2Current Ratio1.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-15.0ROA % (ttm)11.7Higher Current Ratio y-yY
Dividend Yield %5.8Insider Buy (3m)0ROE % (ttm)74.0Less Shares Outstanding y-yY
Payout Ratio %81.0Shares Outstanding M2,427ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 45.96-15%Add 15.52%2,500,048
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 45.96-15%New holding, 270900 sh.270,900
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 45.96-15%Reduce -43.82%5,156,449
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 45.96-15%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 45.96-15%Sold Out0
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 45.96-11%Add 1702.13%423,500
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 45.96-11%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 45.96-11%New holding, 83452 sh.83,452
GSKVanguard Health Care Fund 2013-12-31 Reduce-0.14%$49.31 - $53.68
($51.87)
$ 45.96-11%Reduce -55.18%644,881
GSKWarren Buffett 2013-12-31 Sold Out -0.02%$49.31 - $53.68
($51.87)
$ 45.96-11%Sold Out0
GSKWarren Buffett 2013-09-30 Reduce-0.06%$50.27 - $52.96
($51.54)
$ 45.96-11%Reduce -76.57%345,819
GSKJoel Greenblatt 2013-06-30 Sold Out -0.16%$46.79 - $53.59
($50.77)
$ 45.96-10%Sold Out0
GSKVanguard Health Care Fund 2013-06-30 Reduce-0.1%$46.79 - $53.59
($50.77)
$ 45.96-10%Reduce -26.11%1,611,181
GSKJean-Marie Eveillard 2013-06-30 Reduce-0.05%$46.79 - $53.59
($50.77)
$ 45.96-10%Reduce -100%1
GSKJohn Hussman 2013-03-31 Reduce-0.57%$43.47 - $46.91
($44.97)
$ 45.962%Reduce -95.51%23,500
GSKVanguard Health Care Fund 2013-03-31 Reduce-0.07%$43.47 - $46.91
($44.97)
$ 45.962%Reduce -20.49%2,180,381
GSKJohn Hussman 2012-12-31 Add0.58%$41.9 - $47.45
($44.3)
$ 45.964%Add 2584.62%523,500
GSKDodge & Cox 2012-12-31 Add0.18%$41.9 - $47.45
($44.3)
$ 45.964%Add 5.08%63,302,825
GSKTweedy Browne 2012-12-31 Add0.03%$41.9 - $47.45
($44.3)
$ 45.964%Add 20.16%151,264
GSKJoel Greenblatt 2012-12-31 Reduce-0.09%$41.9 - $47.45
($44.3)
$ 45.964%Reduce -32.53%60,720
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK James Barrow 2014-06-30270,9000.010.02New Buy
GSK Charles Brandes 2014-06-302,500,0480.11.6+15.52%
GSK Joel Greenblatt 2014-06-3083,52800.06+0.09%
GSK Jean-Marie Eveillard 2014-06-30100
GSK John Hussman 2014-06-30323,5000.011.3
GSK Dodge & Cox 2014-06-3060,226,0502.483.1-0.27%
GSK Tweedy Browne 2014-06-30142,1180.010.16-0.34%
GSK PRIMECAP Management 2014-06-305,156,4490.210.3-43.82%
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12283.58view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14228.79view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12283.58view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF Sep 30 2014 
      International Securities For A Diversified Income Portfolio Sep 23 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Guru Stocks at 52-Week Lows: BHP, GSK, EC, VALE, ABB Sep 21 2014 
      Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF Sep 16 2014 
      Guru Stocks at 52-Week Lows: GSK, VOD, LYG, EC, VALE Sep 08 2014 
      3 Dividend Kings From The U.K. I Love To Buy Aug 21 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
      You Should Consider Adding GlaxoSmithKline Based on Tremendous ROE Aug 08 2014 
      Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 


      More From Other Websites
      US won't see an Ebola epidemic: Expert Sep 30 2014
      8:05 am GlaxoSmithKline and GE Healthcare (GE) to collaborate on... Sep 30 2014
      GlaxoSmithKline plc Is Still A Better Pick Than AstraZeneca plc Sep 29 2014
      Ebola Shot Turned Down by WHO Is Best Hope as Virus Rages Sep 26 2014
      Ebola Shot Turned Down by WHO Is Now Best Hope Sep 26 2014
      World Health Leaders' Response When Offered Ebola Vaccine: We'll Get Back to You Sep 25 2014
      Ebola Shot Turned Down by WHO Is Best Hope as Virus Rages Sep 25 2014
      [$$] Glaxo Names Hampton Chairman Sep 25 2014
      Sir Philip Hampton Swaps Royal Bank Of Scotland Group plc For GlaxoSmithKline plc… Should You? Sep 25 2014
      R.B.S. Chairman to Step Down Sep 25 2014
      Glaxo Names RBS’s Hampton as Chairman, Replacing Gent Sep 25 2014
      GSK To Name RBS' Hampton As Next Chairman Sep 25 2014
      Biotech Firm Adaptimmune Attracts $104 Million Investment Sep 24 2014
      Gilead's New HIV Drug Key To Long-Term Strategy Sep 24 2014
      Why GlaxoSmithKline (GSK) Stock Rose Today Sep 24 2014
      Glaxo Said Planning to Name RBS’s Hampton as Chairman Sep 24 2014
      GSK To Name RBS's Hampton As Next Chairman Sep 24 2014
      Why GlaxoSmithKline plc Should Lag The FTSE 100 This Year Sep 24 2014
      Glaxo Fined Roughly $484M in China Bribery Probe Sep 22 2014
      How Will GlaxoSmithKline (GSK) Stock React To Shareholder Skepticism? Sep 22 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK